about
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets.Modeling potential time to event data with competing risks.Colorectal cancer predicted risk online (CRC-PRO) calculator using data from the multi-ethnic cohort study.Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer.An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223A simulation model of colorectal cancer surveillance and recurrence.ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinomaTemporal trends in percutaneous coronary intervention--associated acute cerebrovascular accident (from the 1998 to 2008 Nationwide Inpatient Sample Database).Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an R0 resection for gastric cancer.Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsA hybrid approach to survival model building using integration of clinical and molecular information in censored data.A nomogram for individualized estimation of survival among patients with brain metastasisDevelopment of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer.Comparative effectiveness of screening strategies for Lynch syndrome.Robot-assisted versus other types of radical prostatectomy: population-based safety and cost comparison in Japan, 2012-2013Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancerNonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group.New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort.High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health systemOn Risk Estimation versus Risk Stratification in Early Prostate Cancer.Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.Empirical Treatment Effectiveness Models for Binary Outcomes.A nomogram to predict the probability of passing the American Board of Internal Medicine examination.Multicenter Comparison of Machine Learning Methods and Conventional Regression for Predicting Clinical Deterioration on the WardsDeriving benefit of early detection from biomarker-based prognostic models.Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.Development and validation of a 32-gene prognostic index for prostate cancer progression.Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumoursUnmet needs in the prediction and detection of metastases in prostate cancer.Predicting survival after curative colectomy for cancer: individualizing colon cancer staging.Prediction of morbidity and mortality in patients with type 2 diabetesThe prognostic value of kidney transplant center report cards.Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer.Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013
P50
Q26852544-885BC2E1-750B-4C00-B7F5-D787237819D6Q30607290-B83637C2-7913-4EF1-844F-1D38CAE52002Q30669557-18D7A26B-FAEB-4D85-92F7-05606BA5423DQ30726318-42D904BF-529A-4503-B5B6-5A44598112D8Q30975500-B5579EB8-16B2-4A0B-BEA0-CB5C2C54CBE0Q31112817-360D01B8-45F8-4A3C-85B2-55E0E63BBE26Q33608134-15B750DB-8C2D-475F-8BC3-89FBB00D5C0EQ33613715-E85A6DAB-6B25-4C0E-BB4F-49354C65EEB2Q33758217-7E6A62A9-2500-4161-AAE8-522B446216A6Q33874044-2A40EB78-145C-490C-93E1-3B144F32ACC0Q33881033-633F0123-97A1-4606-B390-8C429AF600EDQ33988984-73C974D9-A343-4E31-8C70-0BA821BC4AEDQ34013808-08349A1C-2A50-47B1-8619-BCC7D1DDD78DQ34164635-02D2036F-13F8-4B44-B380-F97ADE793518Q34250819-1D424966-25D1-4E7D-B21D-6E180A76DEEFQ34406622-D94E0DC5-900F-4493-AAE3-3D960C2DD94BQ35474031-7A15DE8E-6340-4C5D-9F94-D62FBDCECEC2Q35713472-06925ED9-F4A8-4280-95FE-185D24F8C69FQ35722781-8ADFDF78-55FE-4274-B0A5-0FE02AE92821Q35760036-72055C30-D92D-41DC-B07C-24048978CF6AQ35760969-6718A950-EB18-4E84-908E-9D33744D920EQ35775237-28896DFA-39A5-4D37-8CFA-72D688FC8B85Q35875135-9229928D-9746-4591-9B29-0115855B29C8Q35884562-24683073-6833-4D43-A558-79FF69086ADEQ36092345-C6B31DF2-D62B-41E1-9AE5-AF14EC8304F6Q36104725-103131A0-95AD-4CE1-BF67-52FE0C734A13Q36132619-E53D2D73-F72C-45B2-85A7-4021B636C6FAQ36328972-B1E2EC7C-F5B0-4704-A41C-F4D02353A5AAQ36530613-451DE0C8-C905-48A4-AE4D-4E512D9E429FQ36623424-F8C07A99-5E38-4681-9BF1-E99684125636Q36739758-B2D80777-3EA7-4D31-A5A9-59B227EB1267Q36762398-513D529C-736B-441E-8FF6-CA46A4CD7756Q36853969-53847DCE-8BA1-4581-826F-1DE0A2E6E654Q36871680-1B75447E-A10D-4688-B240-4CA1624198E8Q36875387-3247B4F0-188F-4CA1-921B-8E2FB0979E15Q36936666-683FC29D-E83E-4849-A210-49AD52C31350Q36964964-62AAC621-B56A-413F-826D-E98A16C465CEQ36986295-D1D8936E-7416-4CB5-87D4-BFB1D737DFBAQ37043425-6BF1E148-DCBC-4A99-AF0F-883A450DAEFBQ37058711-D6250D2F-9EA8-44E2-8B40-79A8C330BEE6
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-3840-4161
@en
name
Michael W Kattan
@ast
Michael W Kattan
@en
Michael W Kattan
@es
Michael W Kattan
@nl
type
label
Michael W Kattan
@ast
Michael W Kattan
@en
Michael W Kattan
@es
Michael W Kattan
@nl
altLabel
Michael Kattan
@en
prefLabel
Michael W Kattan
@ast
Michael W Kattan
@en
Michael W Kattan
@es
Michael W Kattan
@nl
P108
P106
P1153
57202963994
57204781700
P21
P2798
P31
P496
0000-0002-3840-4161